HCPCS Level II Q2049: Doxorubicin Hydrochloride Liposomal Injection, 10 mg
HCPCS Level II code Q2049 represents an injection of doxorubicin hydrochloride, liposomal formulation (imported Lipodox) in a 10 mg presentation; the service is an oncology chemotherapy administration typically provided as an intravenous infusion in an outpatient infusion center or hospital outpatient department for treatment of cancer.
For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.
Customize your policy alerts
Sign up for hcpcs Q2049 policy alerts
Get alerted when payer policies referencing Q2049 are released or updated.
Monitor payer policy activity